Olanzapine vs Quetiapine: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Olanzapine blocks histamine H1, serotonin 5-HT2C, and muscarinic M3 receptors with high affinity, creating the most severe metabolic syndrome of any antipsychotic. This receptor blockade drives intense appetite stimulation, insulin resistance, and dyslipidemia that cascade into nutrient depletion: vitamin D gets sequestered in expanding adipose tissue, B vitamins are consumed by stressed glucose metabolism, and mitochondrial CoQ10 is depleted by the metabolic inflammatory load. The 30-hour half-life maintains these effects continuously.
Olanzapine achieves 60% bioavailability with a 30-hour half-life and 93% protein binding, providing sustained receptor blockade and uninterrupted metabolic disruption throughout each dosing interval.
- ✓Most effective antipsychotic for treatment-resistant schizophrenia and acute mania
- ✓30-hour half-life provides stable blood levels with once-daily dosing
- ✓IM formulation available for acute agitation management in emergency settings
- ✓Potent sedation useful for patients with severe insomnia alongside psychosis
- ✗Worst metabolic profile of any antipsychotic — 12–15 lbs average first-year weight gain
- ✗FAERS death-associated rate of 9.6% reflecting severe metabolic complications
- ✗Insulin resistance can progress to type 2 diabetes within months of initiation
- ✗93% protein binding limits dose flexibility and increases drug accumulation risk
Treatment-resistant psychosis and acute mania where other antipsychotics have failed, with commitment to aggressive metabolic monitoring.
Quetiapine blocks a remarkable 25 molecular targets (vs olanzapine's 11), including histamine H1, serotonin 5-HT2A/2C, dopamine D2, and adrenergic alpha-1 receptors. The H1 and 5-HT2C blockade drives metabolic effects similar to olanzapine but at moderately lower intensity. Quetiapine's shorter 6-hour half-life means receptor blockade cycles on and off more rapidly, allowing partial metabolic recovery between doses. The metabolic disruption still depletes vitamin D through adipose sequestration, B vitamins through glucose stress, and CoQ10 through mitochondrial impairment.
Quetiapine has only 9% oral bioavailability with a short 6-hour half-life and 83% protein binding, requiring multiple daily doses for schizophrenia but often used once at bedtime for sleep augmentation in mood disorders.
- ✓Shorter 6-hour half-life allows partial metabolic recovery between doses
- ✓Broad indication list: schizophrenia, bipolar mania/depression, and MDD augmentation
- ✓Powerful sedation makes it uniquely useful for patients with severe insomnia
- ✓FAERS logs 87,111 reports with extensive real-world safety data across diverse populations
- ✗25 molecular targets create one of the broadest side effect profiles of any medication
- ✗Still causes significant weight gain and metabolic syndrome — second worst after olanzapine
- ✗Only 9% oral bioavailability — 91% of each dose is lost to first-pass metabolism
- ✗Widely prescribed off-label for insomnia at low doses, exposing patients to antipsychotic-class nutrient depletion unnecessarily
Bipolar depression (unique FDA approval), patients needing sedation alongside mood stabilization, and schizophrenia patients who need broad receptor coverage.
Feature Comparison
| Feature | Olanzapine | Quetiapine |
|---|---|---|
| Drug Class | Atypical antipsychotic (thienobenzodiazepine) | Atypical antipsychotic (dibenzothiazepine) |
| Nutrients Affected | 4 — CoQ10, vitamin D, B vitamins, metabolic | 4 — CoQ10, vitamin D, B vitamins, metabolic |
| Half-Life | 30 hours (continuous) | 6 hours (cyclical) |
| Molecular Targets | 11 receptor targets | 25 receptor targets |
| Metabolic Severity | Worst in class | Second worst in class |
| Bioavailability | 60% | 9% |
| FAERS Death Rate | 9.6% | Moderate |
| Weight Gain | 12–15 lbs first year | 8–12 lbs first year |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both antipsychotics cause significant metabolic disruption that drives nutrient depletion — these are two of the most metabolically damaging medications in psychiatry. Olanzapine is worse: 12–15 lbs average first-year weight gain versus quetiapine's 8–12 lbs, a 9.6% FAERS death-associated rate, and its 30-hour half-life maintains continuous metabolic pressure. Quetiapine's 6-hour half-life allows partial metabolic recovery between doses, providing a modest advantage. However, quetiapine hits 25 molecular targets versus olanzapine's 11, creating a broader side effect profile that includes severe sedation and orthostatic hypotension. For treatment-resistant psychosis, olanzapine's superior efficacy may justify its metabolic cost. For bipolar depression — quetiapine's unique strength — it offers FDA-approved mood benefits that olanzapine lacks. Either way, aggressive metabolic monitoring and supplementation are non-negotiable.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): receptor binding and gene interaction profiles for both drugs across metabolic and neuronal pathways
- [2]FAERS (FDA Adverse Event Reporting System): olanzapine 9.6% death-associated rate; quetiapine 87,111 total adverse reports
- [3]ChEMBL bioactivity database: 11 molecular targets for olanzapine vs 25 for quetiapine across receptor classes
- [4]PubMed PMID 15741488 — Newcomer JW. Second-generation antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1-93
- [5]PubMed PMID 19370587 — De Hert M et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126
Check your medications
Check Free →